What did @royfromtexas actually say?
Roy's argument is straightforward: Republicans who oppose gender-affirming care but visit low-T clinics for testosterone therapy are being hypocritical. He calls it "a do-as-I-say-but-not-what-I-do situation." The political observation is fair enough as a rhetorical point. But the medical comparison he's implying, that TRT and gender-affirming hormone therapy are essentially the same thing, deserves a lot more scrutiny than a TikTok green screen gets.
He doesn't say TRT cures anything, doesn't recommend a dose, and isn't pushing a product. This is a political commentary video, not a health claims video. That matters for how we evaluate it.
Does the science back this up?
The science on testosterone therapy for hypogonadism is well-established and medically distinct from gender-affirming hormone therapy, even though both involve exogenous testosterone. Treating a documented hormone deficiency is a different clinical context than gender transition, though the political optics Roy is pointing to are real.
Hypogonadism, defined as testosterone levels below roughly 300 ng/dL with symptoms, affects an estimated 2-4% of men, according to Bhasin et al. (2010, Journal of Clinical Endocrinology and Metabolism). The American Urological Association and Endocrine Society both recognize TRT as medically indicated for this condition. Gender-affirming testosterone therapy, by contrast, is used to masculinize individuals assigned female at birth, typically targeting the male physiological range. Both are legitimate medical treatments with evidence bases. They are not the same treatment for the same condition, but they do use the same hormone.
What did they get wrong (or right)?
Roy gets the political irony mostly right. Several studies and political scientists have documented the tension between conservative opposition to gender medicine and the rapid embrace of men's health clinics, many of which operate on a direct-to-consumer model that is arguably less regulated than pediatric gender care. That tension is real and documented in public discourse.
Where the video falls short is in the implied equivalency. Roy suggests that getting TRT is essentially the same category of thing as gender-affirming care, which it isn't, medically speaking. TRT for diagnosed hypogonadism is correcting a deficiency in a person's endogenous hormone. Gender-affirming care involves transitioning hormone profiles across biological sex lines. Both involve hormones. Both are legitimate medicine. But they are not interchangeable, and treating them as such to score a political point is a little sloppy.
He's also not wrong that some low-T clinics operate with minimal diagnostic rigor. Research by Baillargeon et al. (2013, JAMA Internal Medicine) found a significant rise in testosterone prescribing without documented deficiency, which complicates the "medically necessary" framing.
What should you actually know?
If you're a man considering TRT, the political debate around this video should be the last thing influencing your decision. What matters is whether you have documented low testosterone with clinical symptoms, confirmed by at least two morning blood tests. Symptoms alone are not enough. Plenty of men feel tired and low-libido for reasons that have nothing to do with testosterone.
The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) are clear: TRT is appropriate for men with confirmed hypogonadism, and it carries real risks including erythrocytosis, infertility, and cardiovascular considerations that a responsible provider should discuss with you. Low-T clinics vary enormously in how rigorously they apply those guidelines.
As for the political argument, Roy is pointing at something real. The selective acceptance of hormone medicine depending on who is receiving it and why is worth examining publicly. But conflating two distinct clinical pathways to make that point doesn't help anyone understand either one better.